Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults

AIDS vaccine evaluation group protocol 022A

Kalpana Gupta, Michael Hudgens, Lawrence Corey, M. Juliana McElrath, Kent Weinhold, David C. Montefiori, Geoffrey J. Gorse, Sharon E. Frey, Michael C. Keefer, Thomas G. Evans, Raphael Dolin, David H. Schwartz, Clayton Harro, Barney Graham, Paul W. Spearman, Mark Mulligan, Paul Goepfert

Research output: Contribution to journalArticle

Abstract

To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in both high-risk and low-risk persons and to evaluate variations in dosing schedule, we conducted a multicenter, randomized, double-blind trial of this vector in combination with recombinant subunit gp120 in 150 HIV-1-seronegative volunteers. The high-titered ALVAC vaccine was well tolerated; adverse events were minimal and not influenced by dosing. At day 728, the cumulative probability of a cytotoxic T-lymphocyte (CTL) response was 76% (95% confidence interval [CI]: 64%-89%) among volunteers receiving vaccine, and the net amount attributable to vaccination was 50% (CI: 16%; 74%). The net probability of a repeated positive CTL response by day 728 was 50% (CI: 21%; 64%). There was a significant difference in CTL response at day 182 between volunteers who had received four doses versus three doses of vCP205 (42% vs. 24%, p = .052). The CTL response was similar in high-risk volunteers and vaccinia-naive volunteers compared with vacciniaimmune volunteers. Neutralizing antibody responses were detected in 95% of vaccinees at day 287, with higher geometric mean titers in recipients of sequential versus simultaneous dosing of the two vaccines and in vaccinia-naive volunteers. This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers.

Original languageEnglish (US)
Pages (from-to)254-261
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume29
Issue number3
StatePublished - Mar 1 2002
Externally publishedYes

Fingerprint

Combined Vaccines
AIDS Vaccines
HIV-1
Volunteers
Safety
Cytotoxic T-Lymphocytes
Population
Vaccinia
Confidence Intervals
Vaccines
Neutralizing Antibodies
Antibody Formation
Appointments and Schedules
Vaccination

Keywords

  • Canarypox vaccines
  • HIV vaccines

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults : AIDS vaccine evaluation group protocol 022A. / Gupta, Kalpana; Hudgens, Michael; Corey, Lawrence; McElrath, M. Juliana; Weinhold, Kent; Montefiori, David C.; Gorse, Geoffrey J.; Frey, Sharon E.; Keefer, Michael C.; Evans, Thomas G.; Dolin, Raphael; Schwartz, David H.; Harro, Clayton; Graham, Barney; Spearman, Paul W.; Mulligan, Mark; Goepfert, Paul.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 29, No. 3, 01.03.2002, p. 254-261.

Research output: Contribution to journalArticle

Gupta, K, Hudgens, M, Corey, L, McElrath, MJ, Weinhold, K, Montefiori, DC, Gorse, GJ, Frey, SE, Keefer, MC, Evans, TG, Dolin, R, Schwartz, DH, Harro, C, Graham, B, Spearman, PW, Mulligan, M & Goepfert, P 2002, 'Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A', Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 3, pp. 254-261.
Gupta, Kalpana ; Hudgens, Michael ; Corey, Lawrence ; McElrath, M. Juliana ; Weinhold, Kent ; Montefiori, David C. ; Gorse, Geoffrey J. ; Frey, Sharon E. ; Keefer, Michael C. ; Evans, Thomas G. ; Dolin, Raphael ; Schwartz, David H. ; Harro, Clayton ; Graham, Barney ; Spearman, Paul W. ; Mulligan, Mark ; Goepfert, Paul. / Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults : AIDS vaccine evaluation group protocol 022A. In: Journal of Acquired Immune Deficiency Syndromes. 2002 ; Vol. 29, No. 3. pp. 254-261.
@article{2620d3f46c704b32be135eda2585e306,
title = "Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A",
abstract = "To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in both high-risk and low-risk persons and to evaluate variations in dosing schedule, we conducted a multicenter, randomized, double-blind trial of this vector in combination with recombinant subunit gp120 in 150 HIV-1-seronegative volunteers. The high-titered ALVAC vaccine was well tolerated; adverse events were minimal and not influenced by dosing. At day 728, the cumulative probability of a cytotoxic T-lymphocyte (CTL) response was 76{\%} (95{\%} confidence interval [CI]: 64{\%}-89{\%}) among volunteers receiving vaccine, and the net amount attributable to vaccination was 50{\%} (CI: 16{\%}; 74{\%}). The net probability of a repeated positive CTL response by day 728 was 50{\%} (CI: 21{\%}; 64{\%}). There was a significant difference in CTL response at day 182 between volunteers who had received four doses versus three doses of vCP205 (42{\%} vs. 24{\%}, p = .052). The CTL response was similar in high-risk volunteers and vaccinia-naive volunteers compared with vacciniaimmune volunteers. Neutralizing antibody responses were detected in 95{\%} of vaccinees at day 287, with higher geometric mean titers in recipients of sequential versus simultaneous dosing of the two vaccines and in vaccinia-naive volunteers. This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers.",
keywords = "Canarypox vaccines, HIV vaccines",
author = "Kalpana Gupta and Michael Hudgens and Lawrence Corey and McElrath, {M. Juliana} and Kent Weinhold and Montefiori, {David C.} and Gorse, {Geoffrey J.} and Frey, {Sharon E.} and Keefer, {Michael C.} and Evans, {Thomas G.} and Raphael Dolin and Schwartz, {David H.} and Clayton Harro and Barney Graham and Spearman, {Paul W.} and Mark Mulligan and Paul Goepfert",
year = "2002",
month = "3",
day = "1",
language = "English (US)",
volume = "29",
pages = "254--261",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults

T2 - AIDS vaccine evaluation group protocol 022A

AU - Gupta, Kalpana

AU - Hudgens, Michael

AU - Corey, Lawrence

AU - McElrath, M. Juliana

AU - Weinhold, Kent

AU - Montefiori, David C.

AU - Gorse, Geoffrey J.

AU - Frey, Sharon E.

AU - Keefer, Michael C.

AU - Evans, Thomas G.

AU - Dolin, Raphael

AU - Schwartz, David H.

AU - Harro, Clayton

AU - Graham, Barney

AU - Spearman, Paul W.

AU - Mulligan, Mark

AU - Goepfert, Paul

PY - 2002/3/1

Y1 - 2002/3/1

N2 - To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in both high-risk and low-risk persons and to evaluate variations in dosing schedule, we conducted a multicenter, randomized, double-blind trial of this vector in combination with recombinant subunit gp120 in 150 HIV-1-seronegative volunteers. The high-titered ALVAC vaccine was well tolerated; adverse events were minimal and not influenced by dosing. At day 728, the cumulative probability of a cytotoxic T-lymphocyte (CTL) response was 76% (95% confidence interval [CI]: 64%-89%) among volunteers receiving vaccine, and the net amount attributable to vaccination was 50% (CI: 16%; 74%). The net probability of a repeated positive CTL response by day 728 was 50% (CI: 21%; 64%). There was a significant difference in CTL response at day 182 between volunteers who had received four doses versus three doses of vCP205 (42% vs. 24%, p = .052). The CTL response was similar in high-risk volunteers and vaccinia-naive volunteers compared with vacciniaimmune volunteers. Neutralizing antibody responses were detected in 95% of vaccinees at day 287, with higher geometric mean titers in recipients of sequential versus simultaneous dosing of the two vaccines and in vaccinia-naive volunteers. This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers.

AB - To test the safety and immunogenicity of a high-titered preparation of ALVAC-HIV vCP205 in both high-risk and low-risk persons and to evaluate variations in dosing schedule, we conducted a multicenter, randomized, double-blind trial of this vector in combination with recombinant subunit gp120 in 150 HIV-1-seronegative volunteers. The high-titered ALVAC vaccine was well tolerated; adverse events were minimal and not influenced by dosing. At day 728, the cumulative probability of a cytotoxic T-lymphocyte (CTL) response was 76% (95% confidence interval [CI]: 64%-89%) among volunteers receiving vaccine, and the net amount attributable to vaccination was 50% (CI: 16%; 74%). The net probability of a repeated positive CTL response by day 728 was 50% (CI: 21%; 64%). There was a significant difference in CTL response at day 182 between volunteers who had received four doses versus three doses of vCP205 (42% vs. 24%, p = .052). The CTL response was similar in high-risk volunteers and vaccinia-naive volunteers compared with vacciniaimmune volunteers. Neutralizing antibody responses were detected in 95% of vaccinees at day 287, with higher geometric mean titers in recipients of sequential versus simultaneous dosing of the two vaccines and in vaccinia-naive volunteers. This high-titered preparation of ALVAC-HIV vCP205 in combination with gp120 was safe and immunogenic in a diverse group of HIV-1-seronegative volunteers.

KW - Canarypox vaccines

KW - HIV vaccines

UR - http://www.scopus.com/inward/record.url?scp=0036500532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036500532&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 254

EP - 261

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -